# Weekly Review: Feb 2-6, 2026

## Summary

| Metric | Value |
|--------|-------|
| Trading Days | 0 |
| Total Trades | 0 |
| Wins | 0 |
| Losses | 0 |
| Net P&L | $0 |

**No trades this week.** Out sick Wed-Fri. Did screening on Mon/Tue but found no actionable setups.

---

## Screening Activity

### Monday Feb 2 — Morning Analysis

Screener ran at 9:35 AM ET. 4 candidates found, all non-biotech:

| Ticker | Change | Sector | Verdict |
|--------|--------|--------|---------|
| FATN | +71.7% | Tech/Networking | Skip — non-biotech, already spiked in PM |
| TIRX | +64.2% | Financial Services | Skip — non-biotech |
| INLF | +45.7% | Industrials | Skip — dead cat bounce from prior day |
| SOAR | +31.7% | Aviation | Skip — non-biotech, choppy |

**Decision:** No trades. Sector discipline held — all candidates were non-biotech.

### Tuesday Feb 3 — Post-Market Screening

Screened AH gainers + ran custom volume spike script on 99 TradingView AH gainers.

| Ticker | AH Change | Verdict |
|--------|-----------|---------|
| LIMN | +31.8% | Skip — already +87% regular session, day 2 of volume |
| FEMY | +14.6% | Skip — tiny AH volume (7K) |
| FEED | +9.8% | Skip — zero AH volume |
| ONCY | +7.9% | Skip — zero AH volume, actually down on day |
| DRMA | +7.6% | Skip — zero AH volume |

5 first-day volume spikes found via custom script — all non-biotech (INHD, DOX, UFI, MAMO, MVIS). Skipped all.

**Decision:** No trades. Correct skips — nothing met entry rules.

### Wednesday Feb 4 – Friday Feb 6

Out sick. No screening or trading.

---

## Rule Violations

None — no trades taken.

---

## Key Lessons

1. **Sector discipline is working** — Correctly skipped all non-biotech candidates on Mon/Tue. W05 showed non-biotech trades (DRCT, XPON, PZG) all lost.

2. **Screening tools improving** — Custom volume spike script (`scripts/ah-screener.py`) added context (first-day vs multi-day spikes) to AH screening. Still needs real-time AH volume source (not just price % gainers).

3. **LIMN retrospective** — The right entry was Feb 2 (day 1 at $0.85, ~50% above prev close). By Feb 3 it was already +87% regular session. Lesson: catch day-1 spikes or let them go.

4. **Dry spells happen** — Two days of screening with zero biotech candidates meeting criteria. The strategy is narrow (biotech, low float, catalyst, <50% above prev close). Patience required.

---

## What Worked

| Pattern | Example | Result |
|---------|---------|--------|
| Sector discipline | Skipped FATN, TIRX, SOAR, INHD | Avoided non-biotech traps |
| Entry rules filter | Skipped LIMN at +87% | Avoided chasing |
| Volume validation | Custom script caught fake AH movers | Better signal quality |

## What Didn't Work

| Pattern | Example | Result |
|---------|---------|--------|
| Narrow biotech filter | 0 biotech candidates in 2 days | No opportunities |
| AH screening data gap | TradingView shows price %, not volume | Missed volume-first approach |

---

## Recommendations

1. **Health first** — Missed 3 days to sickness. No regrets, no trades to go wrong. Rest and recover.

2. **Consider expanding sectors cautiously** — Two days with zero biotech candidates. The scanner learnings from Feb 5 suggest ultra-low float (<500K) stocks with real catalysts can work regardless of sector. Run `--all` flag, filter by catalyst quality.

3. **Improve AH volume screening** — Current workflow starts from price-gainer list. Need a volume-first data source to catch early movers before they show up on gainer lists.

4. **Stay patient** — Zero trades is better than forced trades. W05 proved that FOMO entries (PZG) are the biggest risk.

---

## Trading Plan Updates

No changes to `Day Trading.md` — no new trade data to learn from. Scanner learnings from Feb 3 (AH volume gap) already noted in screening log.
